Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment
Liposome-based targeted drug delivery systems represent a significant advancement in pharmaceutical science, offering distinct advantages that enhance the efficacy and safety of various therapies. These versatile carriers can encapsulate both hydrophilic and hydrophobic drugs, making them particular...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/2/276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718679321706496 |
|---|---|
| author | Andreja Kozak Ernestina Lavrih Georgy Mikhaylov Boris Turk Olga Vasiljeva |
| author_facet | Andreja Kozak Ernestina Lavrih Georgy Mikhaylov Boris Turk Olga Vasiljeva |
| author_sort | Andreja Kozak |
| collection | DOAJ |
| description | Liposome-based targeted drug delivery systems represent a significant advancement in pharmaceutical science, offering distinct advantages that enhance the efficacy and safety of various therapies. These versatile carriers can encapsulate both hydrophilic and hydrophobic drugs, making them particularly valuable in clinical settings. This review explores the critical role of liposomal formulations in improving drug pharmacokinetics and minimizing side effects, especially in oncology, where targeted delivery to tumor cells is essential. Outlining the properties of different types of liposomes, we focus on the effects of these properties on the liposomes’ targeting and drug release capabilities through innovative surface modifications and describe the most common methods of liposome preparation and characterization. Furthermore, this review provides an in-depth analysis of the properties and composition of liposomal-based nanocarriers, with a unique focus on ongoing clinical trials and recently approved therapies. It offers a comprehensive overview of the latest advancements in pre-clinical research and highlights the critical progress in clinical development, offering insights into the clinical impact and regulatory approvals. Ultimately, this review underscores the transformative potential of liposomal nanocarriers in modern therapeutics, suggesting avenues for future innovations and clinical breakthroughs. |
| format | Article |
| id | doaj-art-0685ecf06d0f40e0a0a83d1f50fe0b8f |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-0685ecf06d0f40e0a0a83d1f50fe0b8f2025-08-20T03:12:19ZengMDPI AGPharmaceutics1999-49232025-02-0117227610.3390/pharmaceutics17020276Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer TreatmentAndreja Kozak0Ernestina Lavrih1Georgy Mikhaylov2Boris Turk3Olga Vasiljeva4Department of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, SloveniaDepartment of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, SloveniaDepartment of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, SloveniaDepartment of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, SloveniaDepartment of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, SloveniaLiposome-based targeted drug delivery systems represent a significant advancement in pharmaceutical science, offering distinct advantages that enhance the efficacy and safety of various therapies. These versatile carriers can encapsulate both hydrophilic and hydrophobic drugs, making them particularly valuable in clinical settings. This review explores the critical role of liposomal formulations in improving drug pharmacokinetics and minimizing side effects, especially in oncology, where targeted delivery to tumor cells is essential. Outlining the properties of different types of liposomes, we focus on the effects of these properties on the liposomes’ targeting and drug release capabilities through innovative surface modifications and describe the most common methods of liposome preparation and characterization. Furthermore, this review provides an in-depth analysis of the properties and composition of liposomal-based nanocarriers, with a unique focus on ongoing clinical trials and recently approved therapies. It offers a comprehensive overview of the latest advancements in pre-clinical research and highlights the critical progress in clinical development, offering insights into the clinical impact and regulatory approvals. Ultimately, this review underscores the transformative potential of liposomal nanocarriers in modern therapeutics, suggesting avenues for future innovations and clinical breakthroughs.https://www.mdpi.com/1999-4923/17/2/276liposomesdrug deliverycancer treatmentcontrolled drug releaseclinical trialsclinical applications |
| spellingShingle | Andreja Kozak Ernestina Lavrih Georgy Mikhaylov Boris Turk Olga Vasiljeva Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment Pharmaceutics liposomes drug delivery cancer treatment controlled drug release clinical trials clinical applications |
| title | Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment |
| title_full | Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment |
| title_fullStr | Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment |
| title_full_unstemmed | Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment |
| title_short | Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment |
| title_sort | navigating the clinical landscape of liposomal therapeutics in cancer treatment |
| topic | liposomes drug delivery cancer treatment controlled drug release clinical trials clinical applications |
| url | https://www.mdpi.com/1999-4923/17/2/276 |
| work_keys_str_mv | AT andrejakozak navigatingtheclinicallandscapeofliposomaltherapeuticsincancertreatment AT ernestinalavrih navigatingtheclinicallandscapeofliposomaltherapeuticsincancertreatment AT georgymikhaylov navigatingtheclinicallandscapeofliposomaltherapeuticsincancertreatment AT boristurk navigatingtheclinicallandscapeofliposomaltherapeuticsincancertreatment AT olgavasiljeva navigatingtheclinicallandscapeofliposomaltherapeuticsincancertreatment |